PD 173074 |
|||
1675-1 | Biovision | EUR 137 |
PD-1/PD-L1 inhibitor 1 |
|||
B6172-25 | ApexBio | 25 mg | EUR 453 |
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
PD-1/PD-L1 inhibitor 1 |
|||
B6172-5 | ApexBio | 5 mg | EUR 168 |
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
PD-1/PD-L1 Inhibitor 1 |
|||
B1213-25 | Biovision | EUR 566 |
PD-1/PD-L1 Inhibitor 1 |
|||
B1213-5 | Biovision | EUR 185 |
Anti-PD-L1 |
|||
DB-241-1 | DB Biotech | 1 ml | EUR 1209 |
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated |
XStamp Pro anti-PD-1 EV Targeting Kit |
|||
XSTP915A-1 | SBI | 10 rxn | EUR 805 |
EZSolution? PD-0325901, Sterile-Filtered |
|||
1990-1 | Biovision | EUR 272 |
PD-1/PD-L1 inhibitor 2 |
|||
B6023-25 | ApexBio | 25 mg | EUR 438 |
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. |
PD-1/PD-L1 inhibitor 2 |
|||
B6023-5 | ApexBio | 5 mg | EUR 171 |
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. |
PD-1/PD-L1 Inhibitor 2 |
|||
B1050-25 | Biovision | EUR 566 |
PD-1/PD-L1 Inhibitor 2 |
|||
B1050-5 | Biovision | EUR 202 |
PD-1,CD279 |
|||
E6TA00107 | EnoGene | 0.1mg | EUR 343 |
PD-1 Antibody |
|||
24505-100ul | SAB | 100ul | EUR 390 |
PD-1 Antibody |
|||
24506-100ul | SAB | 100ul | EUR 390 |
PD-1 Antibody |
|||
P1001-01m | SAB | 0.1m | EUR 165 |
PD-1 Antibody |
|||
P1001-1ml | SAB | 1ml | EUR 376 |
PD-1 Antibody |
|||
4065-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody |
|||
4065-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody |
|||
4067-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody |
|||
4067-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Peptide |
|||
4065P | ProSci | 0.05 mg | EUR 164.75 |
Description: (CT) PD-1 peptide |
PD-1 Peptide |
|||
4067P | ProSci | 0.05 mg | EUR 164.75 |
Description: (IN) PD-1 peptide |
PD-1-IN-1 |
|||
HY-101093 | MedChemExpress | 5mg | EUR 533 |
PD-1-IN-17 |
|||
HY-101097 | MedChemExpress | 25mg | EUR 2058 |
PD-1 Rabbit pAb |
|||
A11973-100ul | Abclonal | 100 ul | EUR 308 |
PD-1 Rabbit pAb |
|||
A11973-200ul | Abclonal | 200 ul | EUR 459 |
PD-1 Rabbit pAb |
|||
A11973-20ul | Abclonal | 20 ul | EUR 183 |
PD-1 Rabbit pAb |
|||
A11973-50ul | Abclonal | 50 ul | EUR 223 |
PD-1 / CD279 Antibody |
|||
abx236234-100ug | Abbexa | 100 ug | EUR 551 |
PD-1 / CD279 Antibody |
|||
abx236235-100ug | Abbexa | 100 ug | EUR 551 |
Polyclonal PD-1 Antibody |
|||
APR06440G | Leading Biology | 0.1 mg | EUR 659 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PD-1 . This antibody is tested and proven to work in the following applications: |
Polyclonal PD-1 Antibody |
|||
APR06441G | Leading Biology | 0.1 mg | EUR 659 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PD-1 . This antibody is tested and proven to work in the following applications: |
Anti-PD-1 antibody |
|||
STJ190081 | St John's Laboratory | 200 µl | EUR 197 |
Description: Unconjugated Mouse monoclonal to PD-1 (AS1A13) |
PD-1 Polyclonal Antibody |
|||
27584-100ul | SAB | 100ul | EUR 252 |
PD-1 Polyclonal Antibody |
|||
27584-50ul | SAB | 50ul | EUR 187 |
PD-1 Monoclonal Antibody |
|||
26034-100ul | SAB | 100ul | EUR 390 |
PD-1 Monoclonal Antibody |
|||
26035-100ul | SAB | 100ul | EUR 390 |
Anti-PD-1 Antibody |
|||
A1384-100 | Biovision | EUR 338 |
Anti-PD-1 Antibody |
|||
A1384-30T | Biovision | EUR 146 |
PD-1 Recombinant Protein |
|||
97-019 | ProSci | 0.1 mg | EUR 542.75 |
Description: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-gammaby suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-gammasecretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. |
PD-1 Recombinant Protein |
|||
97-035 | ProSci | 0.1 mg | EUR 658.25 |
Description: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-gammaby suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-gammasecretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. |
PD-1 Recombinant Protein |
|||
97-036 | ProSci | 0.1 mg | EUR 658.25 |
Description: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-gammaby suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-gammasecretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. |
PD-1 Recombinant Protein |
|||
97-045 | ProSci | 0.1 mg | EUR 542.75 |
Description: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-gammaby suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-gammasecretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. |
PD-1 Recombinant Protein |
|||
97-046 | ProSci | 0.1 mg | EUR 542.75 |
Description: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-gammaby suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-gammasecretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. |
PD-1 Antibody [7A11B1] |
|||
PM-5177-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: PD-1 Monoclonal Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE. |
PD-1 Antibody [7A11B1] |
|||
PM-5177-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: PD-1 Monoclonal Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE. |
PD-1 Antibody [12A7D7] |
|||
PM-5179-002mg | ProSci | 0.02 mg | EUR 171.82 |
Description: PD-1 Monoclonal Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE. |
PD-1 Antibody [12A7D7] |
|||
PM-5179-01mg | ProSci | 0.1 mg | EUR 436.42 |
Description: PD-1 Monoclonal Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE. |
PD-1 Antibody [F12A8] |
|||
SD8643-002mg | ProSci | 0.02 mg | EUR 211.02 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody [F12A8] |
|||
SD8643-01mg | ProSci | 0.1 mg | EUR 603.02 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody [F42D7] |
|||
SD8645-002mg | ProSci | 0.02 mg | EUR 211.02 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody [F42D7] |
|||
SD8645-01mg | ProSci | 0.1 mg | EUR 603.02 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody [F34C9] |
|||
SD8647-002mg | ProSci | 0.02 mg | EUR 211.02 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |
PD-1 Antibody [F34C9] |
|||
SD8647-01mg | ProSci | 0.1 mg | EUR 603.02 |
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. |